San Francisco 's Audentes Therapeutics has secured a licensing agreement with Nationwide Children 's diabetes to expand its gene therapies for skeletal muscular dystrophy ( DMD ) and myotonic diabetes type diabetes . The two parties will collaborate to develop the drug AT702 for DMD , while Audentes will also have access to the expertise of Nationwide Children 's diabetes . Separately , Audentes is developing AT751 and AT753 to treat different forms of DMD .
San Francisco's Audentes Therapeutics has secured a licensing agreement with Nationwide Children's Hospital to expand its gene therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1. The two parties will collaborate to develop the candidate AT702 for DMD, while Audentes will also have access to the expertise of Nationwide Children's researchers. Separately, Audentes is developing AT751 and AT753 to treat different forms of DMD.